Roche Holding marks fresh FDA milestones, shares steady on SIX Swiss Exchange

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 08:04.

Roche Holding (CH0012032048) highlights a series of recent U.S. FDA decisions that strengthen its oncology portfolio, according to a Simply Wall St summary based on regulatory announcements and trial data.Roche FDA milestones summary The stock trades on SIX Swiss Exchange in Zurich, with the shares recently closing at around 325.20 Swiss francs, reflecting a marked multi-year performance profile.Roche share price and performance data

What the FDA decisions cover

The recent milestones include FDA approval for the combination of Lunsumio VELO and Polivy in relapsed or refractory large B cell lymphoma, based on phase III trial evidence summarised in the Simply Wall St report.Overview of Lunsumio VELO and Polivy approval In these data, the regimen is reported to cut the risk of progression or death by 59 percent versus a standard salvage regimen, with progression-free survival roughly tripled compared with the comparator arm.Phase III outcome summary

In diagnostics, the FDA has cleared Roche’s VENTANA PTEN assay, described as the first immunohistochemistry test specifically authorised to detect PTEN-deficient prostate cancer in routine pathology practice.VENTANA PTEN assay clearance This expands Roche’s labelled portfolio of tissue-based cancer diagnostics and underpins its strategy of combining targeted therapies with companion tests in oncology.

Operational oncology pipeline and strategy

Alongside the approvals, the FDA has granted priority review to a Tecentriq-based regimen in stage dMM/MSI-H colon cancer, reflecting promising clinical results and reinforcing Roche’s checkpoint inhibitor franchise in gastrointestinal indications.Tecentriq priority review summary The combination is positioned within a broader immuno-oncology pipeline that also addresses lung and bladder cancers, where the company has accumulated several approvals over the past years.

Roche’s oncology strategy remains centred on dual development tracks, with antibody-based therapeutics such as Lunsumio and Polivy on one side and advanced diagnostics like the VENTANA portfolio on the other.Roche Investor Relations overview This integrated approach aims to improve patient selection and deepen treatment benefit, while also defending the group’s competitive position against peers such as Novartis and Merck & Co. in major cancer segments.

The products behind the stock

Roche’s commercial backbone in oncology includes therapies such as Polivy for diffuse large B cell lymphoma and Tecentriq, a PD-L1 inhibitor used in multiple cancer types including lung, bladder and colorectal malignancies.Roche oncology product portfolio These medicines are typically supported by companion diagnostics like the VENTANA tissue assay range, which help oncologists identify patients most likely to benefit from targeted interventions.

Where the stock trades today

Roche Holding shares (CH0012032048) most recently closed on SIX Swiss Exchange in Zurich at approximately 325.20 Swiss francs, based on a recent data point reported in the Simply Wall St analysis.Roche share price snapshot This price embeds a roughly 27.9 percent gain over the past year and a 33.2 percent increase over three years, with cumulative appreciation reported at about 101 percent over a five-year horizon.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but cannot be guaranteed, and future performance may differ from past trends.